1. Different approaches for treating myopic choroidal neovascularization: a network Meta-analysis
- Author
-
Ya-Jun Wu, Yu-Liang Feng, Jia-Song Yang, Hua Fan, and Wen-Sheng Li
- Subjects
myopic choroidal neovascularization ,aflibercept ,bevacizumab ,conbercept ,laser treatment ,ranibizumab ,photodynamic therapy ,Ophthalmology ,RE1-994 - Abstract
AIM: To evaluate the efficacy of intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF), photodynamic therapy (PDT), and laser treatment (LT) for anatomical and functional improvement in myopic choroidal neovascularization (mCNV) patients. METHODS: Two researchers independently searched PubMed, Cochrane Library, Web of Science, and other databases to screen studies comparing best-corrected vision acuity (BCVA) and foveal center thickness (FCT) changes after mCNV treatment. Post-treatment chorioretinal atrophy (CRA) is a secondary outcome indicator. The retrieval time limit is from the database construction to January 30, 2023. RESULTS: A total of 1072 eyes in 16 articles were included. In the RCTs, intravitreal bevacizumab (IVB) and intravitreal ranibizumab (IVR) were superior to PDT (MD=0.18, 95%CI: 0.02, 0.40, MD=0.18, 95%CI: 0.01, 0.42) in improving BCVA of mCNV patients (P
- Published
- 2023
- Full Text
- View/download PDF